Treating Castleman disease: insights into the use and efficacy of monoclonal antibodies
{{output}}
Introduction: Castleman disease (CD) is a rare, heterogeneous group of disorders driven by dysregulated cytokine signaling, particularly interleukin‑6 (IL‑6). Over the past decade, monoclonal antibody (mAb) targeting IL‑6, its... ...
